FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
Basingstoke, UK, 27 October 2004 The U.S. Food and Drug Administration (FDA) today approved FOSRENOL (lanthanum carbonate), a new non-calcium, non-aluminium phosphate binder that reduces high serum phosphate levels in patients with end-stage renal disease (ESRD)....... Without effective treatment, this condition often leads to renal osteodystrophy, a collection of bone diseases that causes bo...On the edge: Are we at risk of an ESRD pandemic?
An analysis of demographic data collected on European and American patients participating in studies for a new non-calcium phosphate binder show striking differences between the causes of renal failure: 14% of European renal failure patients had diabetes as their primary diagnosis, whereas 34% of US patients had this diagnosis. If, as expected by many experts, the incidence of diabetes in Europe...CMS-funded research will assess effectiveness of ESRD disease management models
Ann Arbor, MI -- URREA will evaluate the impact of enrolling patients with end-stage renal disease (ESRD) in disease management systems.... ...This research, funded by the Centers for Medicare and Medicaid Services (CMS), evaluates opportunities for Medicare patients to join integrated care management systems. It focuses on the disease management program structure, processes of care, provider acc...